Castela Guilherme, Providência Joana, Monteiro Madalena, Oliveiros Bárbara, Silva Sónia, Brito Manuel, Machado Egídio, Neto Murta Joaquim, Castelo-Branco Miguel, Correa Zélia
Department of Ophthalmology, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal.
Faculty of Medicine, University of Coimbra (FMUC), Coimbra, Portugal.
Clin Ophthalmol. 2023 Feb 2;17:487-496. doi: 10.2147/OPTH.S398488. eCollection 2023.
We aim to report about effectiveness and safety in the context of our centers' setting in the management of retinoblastoma with intra-arterial chemotherapy (IAC) in a 5-year retrospective analysis of the Portuguese population.
Retrospective analysis of consecutive cases of retinoblastoma selected to initiate IAC between 2015 and 2020, at the Portuguese National Reference Center. All included patients underwent complete ophthalmological evaluation under anesthesia with fundus photography. Diagnosis and classification of retinoblastoma was made according to the International Classification of Intraocular Retinoblastoma (ICRB). The patients were further divided into two groups: Group I for primary IAC and Group II for secondary IAC. Tumor recurrence or relapses, systemic metastasis and deaths were documented. Main efficacy outcome included ocular salvage and recurrence-free survival rates estimated using the Kaplan-Meier method.
Twenty-eight eyes (19 eyes included in Group I and 9 eyes included in Group II) were eligible and a total of 130 IAC procedures were performed, with a median number of sessions of 4 (range 1-8) for each treated eye, during a median follow-up of 21 months (range 4-64). Of the included eyes, 22 (78.6%) were preserved. An overall survival of 100% was achieved. Considering the preserved eyes, the overall median decimal visual acuity achieved at the last visit was 0.15 (range 0.02-0.8). Three patients had permanent adverse events related to IAC (cataract, vitreous hemorrhage and choroidal ischemia). Considering the survival analysis of recurrence, the mean survival without recurrence was 84.2% for Group I and 66.7% for Group II, and the mean survival without enucleation was 78.6% (no events in Group II).
IAC has been shown to be an effective and safe treatment for children with intraocular retinoblastoma. This study demonstrates that IAC is effective even in moderate sample sizes, when a multidisciplinary approach is available.
我们旨在通过对葡萄牙人群进行为期5年的回顾性分析,报告在我们中心环境下动脉内化疗(IAC)治疗视网膜母细胞瘤的有效性和安全性。
对2015年至2020年间在葡萄牙国家参考中心选择开始IAC治疗的视网膜母细胞瘤连续病例进行回顾性分析。所有纳入患者均在麻醉下接受了包括眼底摄影在内的全面眼科评估。视网膜母细胞瘤的诊断和分类依据国际眼内视网膜母细胞瘤分类(ICRB)进行。患者进一步分为两组:I组为初次IAC治疗组,II组为二次IAC治疗组。记录肿瘤复发或再发、全身转移及死亡情况。主要疗效指标包括采用Kaplan-Meier法估计的眼球挽救率和无复发生存率。
28只眼(I组19只眼,II组9只眼)符合条件,共进行了130次IAC治疗,每只治疗眼的治疗次数中位数为4次(范围1 - 8次),中位随访时间为21个月(范围4 - 64个月)。纳入的眼中,22只(78.6%)得以保留。总体生存率达到100%。就保留的眼睛而言,末次随访时的总体中位小数视力为0.15(范围0.02 - 0.8)。3例患者出现与IAC相关的永久性不良事件(白内障、玻璃体出血和脉络膜缺血)。考虑复发的生存分析,I组无复发生存率平均为84.2%,II组为66.7%,无眼球摘除生存率平均为78.6%(II组无事件发生)。
IAC已被证明是治疗眼内视网膜母细胞瘤患儿的一种有效且安全的治疗方法。本研究表明,当采用多学科方法时,即使样本量适中,IAC也是有效的。